Review



control pasmcs  (Lonza)


Bioz Verified Symbol Lonza is a verified supplier
Bioz Manufacturer Symbol Lonza manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Lonza control pasmcs
    Control Pasmcs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/control+pasmcs/10__2478_slash_jtim___2022___0051-60-3-8
    Average 90 stars, based on 1 article reviews
    control pasmcs - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Control:

    Article Title: Inhibition of heterogeneous nuclear ribonucleoproteins A1 and oxidative stress reduces glycolysis <i>via</i> pyruvate kinase M2 in chronic thromboembolic pulmonary hypertension
    Article Snippet: .. In addition, the control PASMCs were purchased from Lonza and Sciencell (Lonza, Gampel, Switzerland. .. Cat#: CC-2581; Sciencell, Santiago, USA.

    Article Title: Upregulation of Oct-4 isoforms in pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension
    Article Snippet: .. Control PASMCs were purchased from Lonza and maintained in culture at low passage (<6) in SM growth medium (SmGM). ..



    Similar Products

    control pasmcs  (Lonza)
    90
    Lonza control pasmcs
    Control Pasmcs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/control+pasmcs/10__2478_slash_jtim___2022___0051-60-3-8
    Average 90 stars, based on 1 article reviews
    control pasmcs - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    control donor paecs and pasmcs  (Lonza)
    90
    Lonza control donor paecs and pasmcs
    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH <t>PASMCs</t> <t>and</t> <t>PAECs</t> following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.
    Control Donor Paecs And Pasmcs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/control+donor+paecs+and+pasmcs/pmc06941156-126-7-11
    Average 90 stars, based on 1 article reviews
    control donor paecs and pasmcs - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    control human pasmc for selected experiments  (Lonza)
    90
    Lonza control human pasmc for selected experiments
    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH <t>PASMCs</t> <t>and</t> <t>PAECs</t> following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.
    Control Human Pasmc For Selected Experiments, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/control+human+pasmc+for+selected+experiments/pmc04967185-138-0-9
    Average 90 stars, based on 1 article reviews
    control human pasmc for selected experiments - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    control human pasmc  (Lonza)
    90
    Lonza control human pasmc
    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH <t>PASMCs</t> <t>and</t> <t>PAECs</t> following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.
    Control Human Pasmc, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/control+human+pasmc/pmc04967185-217-0-9
    Average 90 stars, based on 1 article reviews
    control human pasmc - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pasmc control subjects pulmonary hypertension  (Lonza)
    90
    Lonza pasmc control subjects pulmonary hypertension
    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH <t>PASMCs</t> <t>and</t> <t>PAECs</t> following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.
    Pasmc Control Subjects Pulmonary Hypertension, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/pasmc+from+control+subjects+without+pulmonary+hypertension/pm24135024-464-30-47
    Average 90 stars, based on 1 article reviews
    pasmc control subjects pulmonary hypertension - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pasmc from control subjects  (Lonza)
    90
    Lonza pasmc from control subjects
    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH <t>PASMCs</t> <t>and</t> <t>PAECs</t> following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.
    Pasmc From Control Subjects, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/pasmc+from+control+subjects/pm24135024-464-26-47
    Average 90 stars, based on 1 article reviews
    pasmc from control subjects - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    pasmc from control subjects without pulmonary hypertension  (Lonza)
    90
    Lonza pasmc from control subjects without pulmonary hypertension
    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH <t>PASMCs</t> <t>and</t> <t>PAECs</t> following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.
    Pasmc From Control Subjects Without Pulmonary Hypertension, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/pasmc+from+control+subjects+without+pulmonary+hypertension/10__1161_slash_atvbaha__113__301357-464-30-47
    Average 90 stars, based on 1 article reviews
    pasmc from control subjects without pulmonary hypertension - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    control intrapulmonary pasmcs  (Lonza)
    90
    Lonza control intrapulmonary pasmcs
    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH <t>PASMCs</t> <t>and</t> <t>PAECs</t> following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.
    Control Intrapulmonary Pasmcs, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/control+pasmcs/control+intrapulmonary+pasmcs/10__1164_slash_rccm__201001___0011oc-57-0-11
    Average 90 stars, based on 1 article reviews
    control intrapulmonary pasmcs - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH PASMCs and PAECs following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.

    Journal: International Journal of Molecular Sciences

    Article Title: O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension

    doi: 10.3390/ijms20246299

    Figure Lengend Snippet: The OGT/O-GlcNAc axis regulates VEGF expression by the O-GlcNAc modification of SP-1. ( A ) Representative Immunoblots of VEGF and β-Actin from IPAH PASMCs and PAECs following 5 or 25 mM glucose administration as described in the Methods section. ( B ) PAECs were transfected with scramble or OGT siRNA. OGT and VEGF expression was determined by Immunoblot analysis and quantitated ( C ). Immunoprecipitation was performed using 1 g of a PAEC lysate following different glucose concentrations as described in the methods ( D ) or IP in the presence or absence of OGT inhibitor (Inh) ( E ). The samples were incubated with O-GlcNAc antibody followed by addition of protein L beads, SDS-PAGE, and Western blot analysis. ( F ) A representative Western blot of SP1 and VEGF following SP1 gene silencing using siRNA in the presence of different glucose concentrations. Error bars indicate standard error of the mean (SEM). * p < 0.05 and ** p < 0.01.

    Article Snippet: In some cases, control donor PAECs and PASMCs were obtained from Lonza (Lonza America Inc., NJ, USA).

    Techniques: Expressing, Modification, Western Blot, Transfection, Immunoprecipitation, Incubation, SDS Page

    OGT regulates vascular sprouting in a 3D co-culture model containing IPAH PAECs and PASMCs. ( A ) Representative spheroids from control and IPAH human PAECs:PASMCs (4:1) with treatments and times indicated. ( B ) Box and whiskers plots of the sprouting length. Vascular sprouting was measured using snapshots obtained from an Olympus CKX31 microscope calibrated at the 10X objective. A minimum of 20 fields were used for the sprouting analysis. Arrow indicate multiple sprouts. Abbrv. Ctrl = Control; PH = Idiopathic pulmonary arterial hypertension; OGT Inh. = O-GlcNAc Transferase Inhibitor; and PMA = phorbol-12 myristate 13-acetate. Error bars indicate standard error of the mean (SEM). ANOVA was used for multiple comparisons and *** denotes p < 0.001.

    Journal: International Journal of Molecular Sciences

    Article Title: O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension

    doi: 10.3390/ijms20246299

    Figure Lengend Snippet: OGT regulates vascular sprouting in a 3D co-culture model containing IPAH PAECs and PASMCs. ( A ) Representative spheroids from control and IPAH human PAECs:PASMCs (4:1) with treatments and times indicated. ( B ) Box and whiskers plots of the sprouting length. Vascular sprouting was measured using snapshots obtained from an Olympus CKX31 microscope calibrated at the 10X objective. A minimum of 20 fields were used for the sprouting analysis. Arrow indicate multiple sprouts. Abbrv. Ctrl = Control; PH = Idiopathic pulmonary arterial hypertension; OGT Inh. = O-GlcNAc Transferase Inhibitor; and PMA = phorbol-12 myristate 13-acetate. Error bars indicate standard error of the mean (SEM). ANOVA was used for multiple comparisons and *** denotes p < 0.001.

    Article Snippet: In some cases, control donor PAECs and PASMCs were obtained from Lonza (Lonza America Inc., NJ, USA).

    Techniques: Co-Culture Assay, Control, Microscopy

    Demographic information for human primary PASMCs and PAECs.

    Journal: International Journal of Molecular Sciences

    Article Title: O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension

    doi: 10.3390/ijms20246299

    Figure Lengend Snippet: Demographic information for human primary PASMCs and PAECs.

    Article Snippet: In some cases, control donor PAECs and PASMCs were obtained from Lonza (Lonza America Inc., NJ, USA).

    Techniques: Mutagenesis, Control